About: BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic
Creator	Kumar, Mukesh Sharma, Amit Singh, Rahul Batra, Gitika Medhi, Bikash Mishra, Abhishek Singh, Ashutosh Medhi, Singh, Soloman Singla, Rubal
source	Elsevier; Medline; PMC
abstract	Abstract The impact of COVID-19 is changing country wise and depends on universal immunization policies. COVID-19 badly affects countries that did not have universal immunization policies or having them only for the selective population of countries (highly prominent population) like Italy, USA, UK, Netherland, etc. Universal immunization of BCG can provide great protection against the COVID-19 infection because the BCG vaccine gives broad protection against respiratory infections. BCG vaccine induces expressions of the gene that are involved in the antiviral innate immune response against viral infections with long-term maintenance of BCG vaccine-induced cellular immunity. COVID-19 cases are reported very much less in the countries with universal BCG vaccination policies such as India, Afghanistan, Nepal, Bhutan, Bangladesh, Israel, Japan, etc. as compared to without BCG implemented countries such as the USA, Italy, Spain, Canada, UK, etc. BCG vaccine provides protection for 50 to 60 years of immunization, so the elderly population needs to be revaccinated with BCG. Several countries started clinical trials of the BCG vaccine for health care workers and elderly people. BCG can be uses as a prophylactic treatment until the availability of the COVID-19 vaccine.
has issue date	2020-07-03(xsd:dateTime)
bibo:doi	10.1016/j.aller.2020.05.002
bibo:pmid	32653224
has license	els-covid
sha1sum (hex)	8bddf74924dc4da1cf56b40a5c190e20a22997b0
schema:url	https://doi.org/10.1016/j.aller.2020.05.002
resource representing a document's title	BCG as a game-changer to prevent the infection and severity of COVID-19 pandemic
has PubMed Central identifier	PMC7332934
has PubMed identifier	32653224
schema:publication	Allergol Immunopathol (Madr)
resource representing a document's body	covid:8bddf74924dc4da1cf56b40a5c190e20a22997b0#body_text
is schema:about of	named entity 'Italy' named entity 'population' named entity 'prevent' named entity 'infection' named entity 'elderly' named entity 'antiviral' named entity 'COVID-19' named entity 'policies' named entity 'BCG vaccine' named entity 'population' named entity 'BCG' named entity 'respiratory infections' named entity 'Nepal' named entity 'COVID-19' named entity 'cellular immunity' named entity 'BCG vaccine' named entity 'BCG vaccine' named entity 'COVID-19' named entity 'Canada' named entity 'BCG' named entity 'prophylactic treatment' named entity 'elderly people' named entity 'immunization' named entity 'Afghanistan' named entity 'Spain' named entity 'Bhutan' named entity 'BCG' named entity 'COVID-19 pandemic' named entity 'provide' named entity 'tuberculosis' named entity 'BCG' named entity 'booster doses' named entity 'WHO' named entity 'BCG vaccination' named entity 'BCG' named entity 'high-risk' named entity 'IFN-γ' named entity 'coughing' named entity 'TLRs' named entity 'macrophages' named entity 'herpes' named entity 'adverse reactions' named entity 'BCG' named entity 'BCG' named entity 'viral infection' named entity 'plasma' named entity 'memory B cells' named entity 'MHC' named entity 'BCG vaccine' named entity 'China' named entity 'SARS-CoV2' named entity 'intercellular adhesion molecule' named entity 'organ' named entity 'SARS-CoV2' named entity 'dendritic cells' named entity 'respiratory tract' named entity 'BCG vaccine' named entity 'clinical trial' named entity 'tumor necrosis factor' named entity 'BCG vaccination' named entity 'plasma' named entity 'cytokine' named entity 'pregnant women' named entity 'CD86' named entity 'secretion' named entity 'upregulation' named entity 'secretion' named entity 'BCG' named entity 'BCG' named entity 'pathogen' named entity 'CD80' named entity 'Canada'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software